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Systemic autoimmune diseases exhibit complex symp-
toms that involve multiple organs and cell types. Sys-
temic sclerosis (SSc) is a connective tissue disease char-
acterized by excessive ECM deposition in the skin and
other visceral organs. Although the molecular basis for
SSc is unknown, the presence of highly disease-specif-
ic autoantibodies, including anti–DNA topoisomerase
I (topo I) Ab’s, suggests an autoimmune component to
disease pathogenesis. However, a relationship between
autoimmunity and fibrosis remains unclear. The tight-
skin (TSK) mouse is a genetic model for human SSc.
While the phenotypic characteristics of TSK mice are
not identical to those of human SSc patients, TSK mice
produce autoantibodies against SSc-specific target
autoantigens including topo I, fibrillin 1 (Fbn-1), RNA
polymerase I, collagen type I, and Fcγ receptors (1–3).
The TSK mouse was originally identified (4) as a spon-
taneous mutation exhibiting increased synthesis and
accumulation of collagen and other ECM proteins in
the skin. Although homozygous mice die in utero, het-
erozygous (TSK/+) mice survive but develop cutaneous
fibrosis. TSK/+ mice also have pulmonary emphysema
and cardiac hypertrophies (4). A tandem duplication
within the Fbn-1 gene is suggested to cause the TSK
phenotype (5, 6). Fbn-1 is the major structural protein
of a widely distributed class of connective tissue
microfibrils that are key components of elastic fibers.
Although the duplicated Fbn-1 gene gives rise to an
oversized Fbn-1 protein that results in abnormal
microfibrils (7, 8), a recent study has demonstrated
increased proteolysis of the abnormal microfibrils (7).
Therefore, the phenotypic consequences of the dupli-
cated Fbn-1 gene may only account for lung emphyse-
ma (7). Moreover, transgenic mice expressing a mutat-
ed Fbn-1 gene develop cutaneous hyperplasia, but not
pulmonary emphysema and myocardial hypertrophy
(9). Thus, the role of the Fbn-1 gene in the genesis of tis-
sue hyperplasia and autoimmunity remains unresolved.
Crucial features of most autoimmune diseases include
autoantibody production and skewed humoral
immune responses. Humoral immune responses are
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The tight-skin (TSK/+) mouse, a genetic model for human systemic sclerosis (SSc), develops cuta-
neous fibrosis and autoantibodies against SSc-specific target autoantigens. Although molecular
mechanisms explaining the development of fibrosis and autoimmunity in SSc patients or TSK/+ mice
remain unknown, we recently demonstrated that SSc patients overexpress CD19, an important reg-
ulatory molecule expressed by B lymphocytes. B cells from CD19-deficient mice are hyporesponsive
to transmembrane signals, while B cells overexpressing CD19 are hyperresponsive and generate
autoantibodies. In this study, TSK/+ B cells also exhibited a hyperresponsive phenotype with
decreased surface IgM expression, enhanced serum Ig production, and spontaneous autoantibody
production. Moreover, CD19 tyrosine phosphorylation was constitutively augmented in TSK/+ 
B cells. CD19-mediated [Ca2+]i responses, Vav phosphorylation, and Lyn kinase activity were similarly
enhanced. Studies of TSK/+ mice deficient in CD19 expression demonstrated that CD19 deficiency
significantly decreased skin fibrosis in TSK/+ mice. Additionally, CD19 loss in TSK/+ mice upregu-
lated surface IgM expression and completely abrogated hyper-γ-globulinemia and autoantibody pro-
duction. CD19 deficiency also inhibited IL-6 production by TSK/+ B cells. Thus, chronic B cell acti-
vation resulting from augmented CD19 signaling in TSK/+ mice leads to skin sclerosis possibly
through IL-6 overproduction as well as autoimmunity.
J. Clin. Invest. 109:1453–1462 (2002). doi:10.1172/JCI200215078.
normally regulated by signal transduction molecules
that amplify or inhibit B cell antigen receptor (BCR) sig-
naling during responses to self and foreign antigens
(10). These regulatory molecules include a subset of
functionally interrelated cell surface receptors, such as
CD19 and CD22, and their intracellular signaling com-
ponents, including Lyn protein tyrosine kinase and the
SHP-1 protein tyrosine phosphatase (10). Altered func-
tion or expression of these molecules can influence sus-
ceptibility for autoimmunity. For example, Lyn-defi-
cient mice exhibit glomerulonephritis due to the
presence of immune complexes containing autoanti-
bodies (11). Motheaten viable (mev/mev) mice with 
SHP-1 mutations produce elevated levels of sponta-
neous autoantibodies, hyper-γ-globulinemia, and tissue
deposition of immune complexes (12). Transgenic mice
that overexpress CD19 approximately threefold lose tol-
erance and generate autoantibodies spontaneously (13,
14). Autoantibodies are also found in transgenic mice
with subtle increases of about 20% in CD19 expression
(15). Remarkably, similar increases in CD19 expression
are found on B cells from patients with SSc, with CD19-
overexpressing mice and SSc patients producing char-
acteristic autoantibodies with similar specificities (15).
Therefore, increased CD19 expression and signaling in
B cells may contribute to autoimmunity in SSc patients.
Since CD19 is a general “rheostat” that defines sig-
naling thresholds critical for humoral immune
responses and autoimmunity (10) and CD19 expres-
sion is increased in patients with SSc (15), it was
assessed whether there were also abnormalities in
CD19 expression or function in the TSK mouse model
of SSc. Remarkably, TSK/+ B cells displayed a hyperre-
sponsive phenotype, with enhanced CD19-induced
[Ca2+]i responses and higher levels of constitutive CD19
tyrosine phosphorylation. To further determine an in
vivo role of CD19 signaling in the development of
autoimmunity and skin sclerosis in TSK/+ mice, TSK/+
mice deficient in CD19 expression (CD19–/–TSK/+
mice) were generated. In addition, the loss of CD19
expression significantly downregulated the hyperre-
sponsive phenotype in TSK/+ B cells and eliminated
autoantibody production. CD19 deficiency also inhib-
ited the development of skin fibrosis in TSK/+ mice.
Thus, alterations in CD19-dependent signaling path-
ways contribute to both skin fibrosis and systemic
autoimmunity in TSK/+ mice.
Methods
Mice. CD19–/– (C57BL/6 × 129) mice were generated as
described (16) and backcrossed between 7 and 12 gen-
erations onto the C57BL/6 background before use in
this study. TSK/+ mice with a C57BL/6 genetic back-
ground were purchased from The Jackson Laboratory
(Bar Harbor, Maine, USA). CD19–/–, TSK/+,
CD19–/–TSK/+, and wild-type littermates were generat-
ed by crossing CD19+/–TSK/+ parents. Lack of cell sur-
face CD19 expression was verified by two-color
immunofluorescence staining with flow cytometric
analysis. To verify the TSK/+ genotype, PCR amplifica-
tion of a partially duplicated Fbn-1 gene was carried
out using genomic DNA from each mouse as described
(17). All mice were housed in a specific pathogen–free
barrier facility and screened regularly for pathogens.
Mice used in these experiments were 3 months of age.
All studies and procedures were approved by the Com-
mittee on Animal Experimentation of Kanazawa Uni-
versity Graduate School of Medical Science.
Ab’s and flow cytometric analysis. Ab’s used in this study
included mouse IgA anti–mouse CD19 (MB19-1) mAb
(13); biotinylated or FITC-conjugated anti-IgM
(Southern Biotechnology Associates Inc., Birming-
ham, Alabama, USA); biotinylated or FITC-conjugat-
ed anti-B220 (BD PharMingen, San Diego, California,
USA); phycoerythrin-conjugated (PE-conjugated) anti-
CD5 (BD PharMingen); and PE-conjugated anti-CD23
Ab’s (BD PharMingen). PE-conjugated streptavidin
(Southern Biotechnology Associates Inc.) was used to
reveal staining with biotin-coupled Ab’s. For two-color
immunofluorescence analysis, single-cell suspensions
of lymphocytes from blood, spleen, bone marrow, and
peritoneal lavage were used. Leukocytes (0.5 × 106 to 
1 × 106) were stained at 4°C using predetermined opti-
mal concentrations of Ab’s for 20 minutes as described
(18). Cells with the forward and side light scatter prop-
erties of lymphocytes were analyzed on a FACScan
flow cytometer (BD PharMingen).
B cell purification, immunoprecipitations, and Western blot
analysis. Splenic B cells were purified (>95% B220+) by
removing T cells with anti-Thy1.2 Ab–coated magnet-
ic beads (Dynal Inc., Lake Success, New York, USA), and
subsequently lysed in buffer containing 1% Nonidet 
P-40 as described (19). For CD19 immunoprecipita-
tions, the lysates were incubated with Affigel-10 beads
(Bio-Rad Laboratories Inc., Hercules, California, USA)
bearing anti-CD19 mAb for 4 hours at 4°C. For Vav
immunoprecipitations, the cell lysates were incubated
with protein G-Sepharose beads plus anti-Vav Ab
(Santa Cruz Biotechnology Inc., Santa Cruz, California,
USA). Immunoprecipitated proteins were subjected to
SDS-PAGE and transferred onto membranes for
immunoblotting. These membranes were incubated
with horseradish peroxidase–conjugated anti-phos-
photyrosine Ab (PY99; Santa Cruz Biotechnology Inc.).
These blots were developed using an enhanced chemi-
luminescence kit (Pierce Chemical Co., Rockford, Illi-
nois, USA). To verify equivalent amounts of protein in
each lane, the blots were stripped and reprobed with
Ab’s against Vav or CD19 (Santa Cruz Biotechnology
Inc.). Band intensities were quantified using Quantity
One software (Bio-Rad Laboratories Inc.).
In vitro Lyn kinase assays. Splenic B cell lysates were pre-
cleared and incubated with anti-Lyn Ab’s (Santa Cruz
Biotechnology Inc.) and protein A-Sepharose beads for
3 hours at 4°C (19). The beads were incubated with 10
µg of cdc2(6-20)NH2 peptide (Upstate Biotechnology
Inc., Lake Placid, New York, USA) and 10 µCi of [γ-32P]
ATP for 2 minutes at 25°C. The reactions were termi-
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nated by adding 40% trichloroacetic acid and spotted
onto p81 phosphocellulose paper. Radioactivity was
quantified by scintillation counting.
Measurement of [Ca2+]i. Isolated splenocytes were
loaded with 1 µM indo-1 AM ester (Molecular Probes
Inc., Eugene, Oregon, USA) at 37°C for 30 minutes, and
then stained with FITC-conjugated anti-B220 Ab. For
analysis, the ratio of fluorescence (525/405 nm) for
B220+ cells was determined using an Epics Altra cell
sorter (Beckman Coulter Inc., Miami, Florida, USA).
Base-line fluorescence ratios were collected for 1 minute
before addition of anti-CD19 mAb (40 µg/ml). Fluores-
cence ratios were obtained in real time for 7 minutes fol-
lowing mAb addition. An increase in the fluorescence
ratio indicates an increase in [Ca2+]i.
B cell proliferation. Purified spleen B cells were cultured
in 0.2 ml of culture medium in 96-well flat-bottom
plates with LPS (Sigma-Aldrich, St. Louis, Missouri,
USA), F(ab′)2 anti-mouse IgM Ab’s (Cappel, Durham,
North Carolina, USA), or anti-CD38 mAb (Ab90; BD
PharMingen) for 72 hours. Proliferation was assessed
by the incorporation of [3H]-labeled thymidine (1
µCi/well) added during the last 16 hours of culture, fol-
lowed by scintillation counting. All treatments were
carried out in triplicate cultures.
Antinuclear Ab analysis. Antinuclear Ab’s (ANAs) were
assessed by indirect immunofluorescence staining using
sera diluted 1:50 and HEp-2 substrate cells (Medical &
Biological Laboratories Co., Nagoya, Japan) as described
(15). ANAs were detected using FITC-conjugated F(ab′)2
fragments specific for mouse IgG+IgM+IgA (Southern
Biotechnology Associates Inc.).
ELISAs for autoantibodies. Serum autoantibody levels
were determined by ELISA as described (15). Briefly, 96-
well microtiter plates were coated with single-stranded
DNA (ssDNA; Sigma-Aldrich), double-stranded DNA
(dsDNA; Medical & Biological Laboratories Co.), his-
tone (Sigma-Aldrich), the recombinant human Fbn-1
peptide, or rabbit IgG (Sigma-Aldrich). Plates were
incubated with serum samples diluted 1:100. The
bound Ab’s were detected with alkaline phos-
phatase–conjugated anti-mouse IgG or IgM Ab’s
(Southern Biotechnology Associates Inc.). Anti–topo I
Ab’s were measured with specific ELISA kits (Medical
& Biological Laboratories Co.). The recombinant pep-
tide of the proline-rich C region (amino acids 395–446)
of Fbn-1 was generated as described elsewhere (2, 3).
Relative levels of autoantibodies were determined for
each group of mice using pooled serum samples. Sera
were diluted at log intervals (1:10–1:105) and assessed
for relative autoantibody levels as above except that the
results were plotted as OD versus dilution (log scale).
The dilutions of sera giving half-maximal OD values
were determined by linear regression analysis, thus gen-
erating arbitrary unit per milliliter values for compari-
son between sets of sera.
Mouse Ig isotype-specific ELISAs. To determine Ab con-
centrations in sera, ELISAs were carried out as
described (16), using affinity-purified mouse IgM,
IgG1, IgG2a, IgG2b, IgG3, and IgA (Southern Biotech-
nology Associates Inc.) to generate standard curves.
The relative Ig concentration of individual samples was
calculated by comparing the mean OD obtained for
duplicate wells to a semi-log standard curve of titrated
standard Ab using linear regression analysis.
Histopathological assessment of skin fibrosis. Morphologic
characteristics of skin sections from CD19–/–TSK/+
mice were compared with those of CD19–/–, TSK/+, and
wild-type littermates under a light microscope. All skin
sections were taken from the para-midline, lower back
region (the same anatomic site, to minimize regional
variations in thickness) as full-thickness sections
extending down to the body wall musculature. Tissues
were fixed in 10% formaldehyde solution for 24 hours
and embedded in paraffin. Sections were stained with
hematoxylin and eosin. Hypodermal thickness, which
was defined as the thickness of a subcutaneous loose
connective tissue layer (i.e., the hypodermis or superfi-
cial fascia) beneath the panniculus carnosus, was meas-
ured for multiple transverse perpendicular sections
using an ocular micrometer. Dermal thickness, defined
as the thickness of skin from the top of the granular
layer to the junction between the dermis and subcuta-
neous fat, was also examined. Ten random measure-
ments were taken per section. All of the sections were
examined independently by two investigators in a
blinded fashion. The skin from male mice was general-
ly thicker than that from female mice in spite of the
presence or absence of TSK mutations (data not
shown). Since similar results were obtained when male
or female mice were analyzed separately, only data from
female mice were presented for skin thickness and
hydroxyproline content in this study.
Determination of hydroxyproline content in the skin tissue.
Hydroxyproline is a modified amino acid uniquely
found as a high percentage of collagen. Six-millimeter
punch biopsies from shaved dorsal skin samples were
treated with chloroform/methanol (2:1 vol/vol) to
remove the fat and were dried by centrifugation under
vacuum. Dried samples were weighed, and acid
hydrolyzed for 24 hours at 110°C. The hydroxy lysates
were dried, redissolved in 200 µl of water, and filtered
through millipore filters. Sample aliquots of 20 µl were
diluted tenfold and used for amino acid composition
analysis in an Amino Acid Analyzer (Hewlett-Packard,
Palo Alto, California, USA).
Production of IL-6 and IgG1 by splenic B cells. Purified
splenic B cells (2 × 105) were cultured in 0.2 ml of culture
medium in 96-well flat-bottom plates with F(ab′)2 anti-
mouse IgM Ab (1 µg/ml) plus anti-CD40 mAb (1C10, 10
µg/ml; R&D Systems Inc., Minneapolis, Minnesota,
USA) for 48 hours. IL-6 accumulation in the culture
medium was measured by ELISA (R&D Systems Inc.).
Purified splenic B cells (1 × 105) were cultured with LPS
(20 µg/ml) plus IL-4 (100 ng/ml) for 5 days. IgG1 secret-
ed into the culture medium was determined by ELISA.
Statistical analysis. All data are expressed as mean val-
ues ± SEM. The Mann-Whitney U test was used for
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determining the level of significance of differences
between sample means, and Bonferroni’s test was used
for multiple comparisons.
Results
CD19 expression and signaling in TSK/+ B cells. CD19
expression and signaling were assessed in B cells from
TSK/+ mice. Cell surface CD19 expression levels on
bone marrow, blood, spleen, and peritoneal TSK/+ B
cells were indistinguishable from those found on B
cells from wild-type littermates (data not shown). Sim-
ilarly, the wild-type amounts of CD19 protein were
immunoprecipitated from TSK/+ B cells (Figure 1a).
However, constitutive CD19 tyrosine phosphorylation
was significantly augmented in splenic TSK/+ B cells
compared with wild-type B cells (45% increased, 
P < 0.01, Figure 1a). Consistent with this, constitutive
tyrosine phosphorylation of Vav, a major effector mol-
ecule downstream of CD19 signaling (19, 20), was also
enhanced 3.4-fold in TSK/+ B cells relative to wild-type
B cells (P < 0.01, Figure 1b). Since CD19 regulates Lyn
kinase activity (19, 20), constitutive in vitro Lyn kinase
activity was assessed. Lyn kinase activity was enhanced
by 22% in TSK/+ B cells compared with wild-type B
cells (P < 0.05, Figure 1c). By contrast, CD19 deficiency
in TSK/+ B cells inhibited Lyn kinase activity, which
was 11% lower than that found in wild-type B cells 
(P < 0.05). To further assess CD19 signaling in TSK/+
B cells, [Ca2+]i responses generated by CD19 ligation
were examined. In wild-type B cells, CD19 engagement
using optimal concentrations of a dimeric IgA Ab (40
µg/ml) induces a slow rise in [Ca2+]i (Figure 2a). CD19-
induced [Ca2+]i responses in TSK/+ B cells were signif-
icantly augmented when compared with those in wild-
type B cells. Proliferation of TSK/+ B cells in response
to anti-IgM Ab was significantly increased compared
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Figure 1
CD19 signal transduction in B cells from TSK/+ and wild-type littermates. (a and b) Constitutive tyrosine phosphorylation of CD19 (a) and
Vav (b) in B cells. Splenic B cells were obtained from three mice of each group. Proteins were immunoprecipitated from lysates of unstimu-
lated B cells with either anti-CD19 or anti-Vav Ab’s. Immunoprecipitated proteins were subjected to SDS-PAGE and transferred onto mem-
branes for subsequent anti-phosphotyrosine (anti-pTyr) immunoblotting. All blots were subsequently stripped of anti-pTyr Ab’s and reprobed
with the precipitating Ab’s to verify equivalent amounts of proteins in each lane. Each lane represents results from individual mice but rep-
resents results obtained with at least six sets of mice. (c) Constitutive Lyn kinase activity in B cells. Splenic B cells were solubilized and immuno-
precipitated with anti-Lyn Ab. Immunoprecipitates were then incubated with cdc2(6-20)NH2 peptide and [γ-32P] ATP. The radioactivity
incorporated into cdc2 peptide was quantified by scintillation counting. Relative mean (± SEM) kinase activities are obtained from three
experiments. Kinase activity was shown as percentage of wild-type B cells that were defined as 100%. *P < 0.05.
Figure 2
Activation and proliferation of B cells from TSK/+ and wild-type littermates. (a) [Ca2+]i responses in B cells following CD19 ligation. Spleno-
cytes were loaded with indo-1 AM ester and examined for relative [Ca2+]i levels by flow cytometry after gating on the B220+ population of cells.
Anti-CD19 mAb was added at the indicated time (arrow). An increase in the fluorescence ratio indicates an increase in [Ca2+]i. These results
represent those obtained in four independent experiments. (b) B cell proliferation in response to anti-IgM Ab’s, LPS, and anti-CD38 mAb. Spleen
B cells were cultured for 72 hours with the indicated amounts of anti-IgM Ab’s, LPS, or anti-CD38 mAb. Values represent the mean cpm (± SEM)
of labeled thymidine obtained from triplicate cultures. These results represent those obtained in four independent experiments. *P < 0.05.
with wild-type B cells (22% increase, P < 0.05), but
TSK/+ B cells exhibited normal proliferation to LPS or
anti-CD38 mAb (Figure 2b). Thus, the CD19 signaling
pathway appeared to be constitutively activated in
TSK/+ B cells, which resulted in increased early B cell
responses mediated by CD19 and enhanced BCR-
mediated proliferation.
CD19 deficiency normalizes TSK/+ B cell hyperresponsive-
ness. Constitutively activated B cells, including B cells
overexpressing CD19, express reduced levels of cell sur-
face IgM as a consequence of augmented signaling (18,
21, 22). By contrast, CD19-deficient B cells, which are
hyporesponsive, express elevated levels of cell surface
IgM (13, 16, 22). Consistent with a hyperresponsive
phenotype of TSK/+ B cells and upregulated CD19 sig-
naling, blood B cells had a 55% decrease in surface IgM
expression relative to B cells from wild-type littermates
(P < 0.0001, Figure 3). Circulating B cells from CD19–/–
mice demonstrated 137% higher surface IgM levels
than did wild-type B cells (P < 0.01). CD19 deficiency
in TSK/+ mice resulted in 125% increased IgM expres-
sion on circulating B cells relative to wild-type B cells
(P < 0.0001). Surface IgM levels on splenic B cells from
TSK/+ mice were 10% lower than those of wild-type B
cells (P < 0.05). By contrast, splenic B cells from
CD19–/– and CD19–/–TSK/+ mice had significantly ele-
vated IgM expression levels compared with wild-type
B cells (34%, P < 0.001, and 38%, P < 0.0001, respec-
tively). CD23 expression levels, an indicator of B cell
activation, on splenic B cells from TSK/+ mice were
significantly 47% higher than those found in wild-type
B cells (P < 0.005) but were normal on CD19–/–TSK/+
B cells. Expression levels of MHC class II antigens 
(I-A), CD44, CD54, and CD86 were similar for TSK/+
and wild-type B cells (data not shown). Thus, TSK/+ B
cells exhibited the characteristic hyperresponsive phe-
notype due to abnormal basal signaling thresholds.
The effect of the TSK/+ mutation on B cell respon-
siveness was assessed by determining serum Ig levels in
TSK/+ mice (Figure 4). TSK/+ mice had significantly
elevated IgM (P < 0.05), IgG1 (P < 0.05), IgG2a 
(P < 0.0005), and IgG2b (P < 0.001) levels compared with
those of wild-type littermates, while IgG3 and IgA levels
were not significantly different from those of wild-type
littermates. By contrast, CD19–/– mice had significantly
decreased IgG1 (P < 0.001), IgG3 (P < 0.0001), and IgA
(P < 0.01) levels compared with wild-type littermates.
Similarly, CD19–/–TSK/+ mice had significantly lower
IgG1 and IgG3 concentrations compared with TSK/+
and wild-type littermates (P < 0.01), while levels of other
isotypes were similar to those found in wild-type litter-
mates. Thus, TSK/+ mice exhibited hyper-γ-globuline-
mia that was dependent on CD19 signal transduction.
CD19 loss abrogated autoantibody production in TSK/+
mice. ANAs in CD19–/–, TSK/+, CD19–/–TSK/+, and wild-
type littermates were determined by indirect immuno-
fluorescence staining using HEp-2 cells as the sub-
strate. ANAs with a homogenous chromosomal
staining pattern were detected in 33% (10/30) of TSK/+
mice but were rarely detectable in CD19–/– (6%, 1/16),
CD19–/–TSK/+ (6%, 1/16), and wild-type (6%, 2/31) lit-
termates. Since a homogenous staining pattern gener-
ally results from a variety of autoantibodies including
Ab’s against topo I, dsDNA, and histone, autoantibody
specificities were assessed by ELISA (Figure 5). The
dilution of sera giving half-maximal OD values in
ELISAs was also determined to generate arbitrary units
per milliliter that could be directly compared between
mutant and wild-type littermates. Pooled sera from
TSK/+ mice had mean IgM and IgG anti–topo I Ab lev-
els that were 37- and 3.8-fold higher than those found
in wild-type littermates (P < 0.01 and P < 0.05, respec-
tively). TSK/+ mice had mean IgM Ab levels to dsDNA
and histone that were 2.6-fold (P < 0.05) and 4.6-fold 
(P < 0.05) higher than those found in wild-type litter-
mates, respectively, whereas IgG Ab levels to ssDNA,
dsDNA, and histone were similar for TSK/+ and wild-
type littermates. Mean IgM and IgG anti–Fbn-1 Ab 
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Figure 3
Cell surface IgM or CD23 expression and B cell development in
mutant and wild-type littermates. (a) Representative two-color indi-
rect immunofluorescence staining with flow cytometric analysis of B
cells. Values represent the percentage of the total gated lymphoid cell
population that falls into the indicated gates. Horizontal dashed
lines indicate mean IgM or CD23 expression of wild-type B cells to
highlight differences in expression levels. These results represent those
obtained with at least six mice of each genotype. (b) Relative cell sur-
face IgM or CD23 densities were determined by comparing mean 
(± SEM) linear fluorescence intensity channel numbers for immuno-
fluorescence staining between B cells from mice of each genotype 
(n = 6 for each). *P < 0.05, **P < 0.01 vs. wild-type littermates.
levels were significantly 52% (P < 0.005) and 2.0-fold 
(P < 0.05) higher in TSK/+ mice than those in wild-type
littermates. TSK/+ mice also had rheumatoid factor
(RF) levels that were increased 3.3-fold relative to those
of wild-type littermates (P < 0.01). By contrast, CD19–/–
and CD19–/–TSK/+ mice had decreased IgM and IgG
Ab’s reactive with topo I, ssDNA, dsDNA, histone, and
Fbn-1 relative to those of wild-type littermates 
(P < 0.05), while CD19–/– and CD19–/–TSK/+ mice had
RF levels similar to those of their wild-type littermates.
Thus, loss of the CD19 signaling pathway dramatical-
ly inhibited autoantibody production in TSK/+ mice.
B cell development in TSK/+ and CD19–/–TSK/+ mice. B
cell development in the bone marrow was normal in
TSK/+ mice (Table 1). Both the frequency and the num-
ber of blood, tissue, and peritoneal B cells were also nor-
mal in TSK/+ mice (Figure 3 and Table 1). Unexpected-
ly, however, TSK/+ mice had significantly decreased
numbers of peritoneal CD5+ B220low B1 cells compared
with wild-type littermates (70% reduction, P < 0.05),
while CD5– B220hi conventional B2 cell numbers were
comparable with those of wild-type littermates. Thus, B
cell development in TSK/+ mice was normal except for
reduced peritoneal B1 cell development. By comparison,
peripheral B cell numbers in CD19–/–TSK/+ mice were
reduced, but similar to those normally found in CD19–/–
littermates, with a significant reduction (∼90%, P < 0.01)
in peritoneal B1 cells. Thus, CD19 deficiency reduced
the numbers of peripheral B cells in TSK/+ mice but did
not severely limit B cell development.
CD19 loss attenuated the development of skin fibrosis in
TSK/+ mice. Skin fibrosis in TSK/+, CD19–/–,
CD19–/–TSK/+, and wild-type littermates was assessed
by histopathology of the full-thickness skin sections
from the back. The dermal thickness (the thickness
from the top of the granular layer to the junction
between the dermis and subcutaneous fat) was similar
among TSK/+ (32 ± 2 µm), CD19–/– (33 ± 2 µm),
CD19–/–TSK/+ (33 ± 2 µm), and wild-type (34 ± 3 µm)
littermates (Figure 6a). The thickness of subcutaneous
fat and panniculus carnosus was also similar among
mutant and wild-type littermates (data not shown).
Thus, increased skin fibrosis in TSK/+ mice was not
due to hyperplasia of dermal connective tissue but
resulted from hyperplasia of a subcutaneous loose
connective tissue layer (i.e., the hypodermis or super-
ficial fascia) beneath panniculus carnosus (Figure 6a).
The hypodermal thickness in TSK/+ mice was
increased ninefold compared with wild-type litter-
mates (P < 0.0001, Figure 6b). CD19–/–TSK/+ mice
showed a moderate thickening of hypodermal tissue,
which was significantly 36% thinner than that found
in TSK/+ mice (P < 0.001) but remained significantly
thicker than that of wild-type littermates (P < 0.001).
Hypodermal thickness was similar in wild-type and
CD19–/– littermates.
Cutaneous fibrosis was also assessed by quantifying
the hydroxyproline content of 6-mm punch biopsies
from skin samples of mutant and wild-type littermates
(Figure 6c). Hydroxyproline content in TSK/+ mice was
increased by 26% relative to that in wild-type litter-
mates (P < 0.0005). CD19 deficiency reduced hydrox-
yproline content by 13% in TSK/+ mice (P < 0.01), but
hydroxyproline content remained significantly higher
than that in wild-type littermates (P < 0.01). Hydrox-
yproline content was comparable between wild-type
and CD19–/– littermates. CD19 deficiency did not sig-
nificantly affect the onset or severity of pulmonary
emphysema and cardiac hypertrophy in TSK/+ mice
(data not shown). Thus, B cells contributed to the
induction of skin fibrosis in TSK/+ mice through a
CD19-dependent pathway.
CD19 deficiency suppressed overproduction of IL-6 by
TSK/+ B cells. It has been suggested that IL-6 produc-
tion contributes to skin fibrosis as well as the
immunological abnormalities found in human SSc
(23, 24). IL-6, a pleiotropic cytokine produced by B
cells and various other cell types, induces the produc-
tion of collagen and glycosaminoglycans by dermal
fibroblasts, stimulates the proliferation and differen-
tiation of B cells, and enhances Ab production (25).
Therefore, IL-6 production by splenic B cells from
mutant and wild-type littermates was assessed. Super-
natant fluid from B cell cultures contained only negli-
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Figure 4
Serum Ig levels in mutant and wild-type littermates. Ig levels were
determined by isotype-specific ELISAs. Horizontal bars represent
mean Ig levels. Statistical analysis is provided in Results.
gible quantities of IL-6 (Figure 7a). By contrast, TSK/+
B cells stimulated with anti-IgM plus anti-CD40
mAb’s produced amounts of IL-6 that were 78% high-
er than those found in cultures of stimulated wild-type
B cells (P < 0.05). CD19 deficiency significantly inhib-
ited IL-6 production by TSK/+ B cells (55%, P < 0.05)
but did not inhibit IL-6 production by wild-type B
cells. Thus, IL-6 production was augmented in TSK/+
B cells through a CD19-dependent signaling pathway.
CD19 deficiency inhibited IL-4–induced IgG1 overproduc-
tion by TSK/+ B cells. It has been demonstrated that IL-4
plays a critical role in the cutaneous hyperplasia of
TSK/+ mice, since deficiency of IL-4 or IL-4 receptor α
(IL-4Rα) inhibits skin fibrosis and autoantibody pro-
duction (17, 26). IL-4 activates B cells that secrete IgG1
in vitro in the presence of LPS. Therefore, responsive-
ness of TSK/+ B cells to IL-4 was assessed by IgG1 pro-
duction of splenic B cells. Background levels of IgG1
secretion were similar for mutant and wild-type litter-
mates (Figure 7b). Stimulation of TSK/+ B cells with
IL-4 plus LPS resulted in IgG1 secretion that was 38%
higher than that of wild-type B cells (P < 0.05). The
CD19 loss in TSK/+ B cells inhibited IgG1 production
(40%, P < 0.05). However, IgG1 production by CD19–/–
B cells was normal as previously reported (27). Thus,
TSK/+ B cells exhibited enhanced activation by IL-4
that was eliminated by CD19 deficiency.
Discussion
The current study demonstrates that B cells are critical
for the development of skin fibrosis in the TSK model of
SSc (Figure 6). Specifically, B cells in TSK/+ mice dis-
played a hyperresponsive phenotype characterized by
downregulated surface IgM expression and upregulated
CD23 expression (Figure 3), constitutively enhanced
CD19 and Vav tyrosine phosphorylation (Figure 1, a and
b), augmented Lyn kinase activity (Figure 1c), increased
CD19-induced [Ca2+]i responses (Figure 2a), and hyper-
γ-globulinemia (Figure 4). TSK/+ B cells also exhibited
augmented proliferative response to BCR ligation (Fig-
ure 2b). However, B cell surface receptor–mediated sig-
naling was not globally abnormal, since proliferation in
response to LPS or anti-CD38 mAb was normal in
TSK/+ B cells. Most significant, however, was that the
hypodermal thickness and collagen deposition of skin
were significantly decreased in TSK/+ mice due to CD19
deficiency (Figure 6). In addition, autoantibody levels
(Figure 5), IL-6 production by activated B cells (Figure
7a), and IgG1 secretion by B cells activated with IL-4
(Figure 7b) were reduced in TSK/+ mice by CD19 defi-
ciency. Thus, a CD19-dependent signaling pathway in B
cells contributes to the development of systemic autoim-
munity and skin sclerosis in TSK/+ mice.
Consistent with a role for B cells in TSK/+ mice,
adoptive transfer of both T and B cells from TSK/+
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Figure 5
Anti–topo I, anti-ssDNA, anti-dsDNA,
anti-histone, anti–Fbn-1, and RF Ab
levels in sera from mutant and wild-
type littermates. Relative autoantibody
levels were determined by Ig sub-
class–specific ELISA. Horizontal bars
represent mean autoantibody levels.
Values in parentheses represent the
dilutions of pooled sera giving half-
maximal OD values in autoantigen-
specific ELISAs, which were deter-
mined by linear regression analysis to
generate arbitrary units per milliliter
that could be directly compared
between each group of mice. Statistical
analysis is provided in Results.
mice induces cutaneous collagen deposition and
autoantibody production in wild-type mice, while the
infusion of purified T cells does not lead to the devel-
opment of TSK syndrome (28). In addition, the devel-
opment of skin fibrosis correlates closely with serum
anti–topo I Ab levels in TSK/+ mice (29). Although Kas-
turi et al. have reported that mature B cell loss does not
abrogate dermal thickening in TSK/+ mice (6), this dif-
ference in conclusions may result from the measure-
ment of different parameters. The current study (Fig-
ure 6) and other previous studies (4, 30–32) have shown
that dermal thickness is similar in TSK/+ and wild-type
littermates, but the hypodermal thickness, including a
subcutaneous connective tissue layer, is significantly
increased in TSK/+ mice relative to wild-type litter-
mates (4, 30–32). In fact, Green et al. originally charac-
terized the cutaneous pathology in TSK/+ mice as a
massive increase in the subcutaneous tissue with no
obvious changes present in the dermis and epidermis
(4). Another study has reported that TSK/+ BALB/c
mice deficient in both B and T cell function develop
cutaneous fibrosis that is indistinguishable from that
found in TSK/+ mice (31). This result conflicts not
only with the current study but also with previous
studies where immunocompetent cells contributed to
the development of skin fibrosis in TSK/+ mice (28,
32). However, the BALB/c genetic background may
affect cutaneous fibrosis in TSK/+ mice, since the
hypodermal thickness of TSK/+ BALB/c mice is only
twofold increased compared with the nine- to tenfold
increase observed on a C57BL/6 background (Figure 6)
(30). Thus, the contribution of B cells to the pathogen-
esis of TSK syndrome may not be consistent across all
genetic backgrounds.
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Figure 6
Skin fibrosis in dorsal skin from mutant and wild-type littermates.
(a) Representative histologic sections stained with hematoxylin and
eosin are shown (×40). An asterisk indicates the dermis, and double
asterisks show the subcutaneous loose connective tissue layer (i.e.,
the hypodermis or superficial fascia) beneath the panniculus
carnosus (arrow). These results represent those obtained with at
least ten mice of each genotype. Skin fibrosis was assessed by quan-
titatively measuring hypodermal thickness (b) and skin hydroxypro-
line content (c). The hypodermal thickness was measured under a
light microscope as the thickness of the hypodermis or superficial fas-
cia beneath the panniculus carnosus. The quantity of hydroxyproline
is expressed as µg per 6-mm punch biopsy. Horizontal bars represent
mean hypodermal thickness (b) and mean hydroxyproline content
(c). Statistical analysis is provided in Results.
Table 1
B lymphocyte development in CD19–/–, TSK/+, CD19–/–TSK/+, and wild-type littermates
Frequency (%) and number (# 10–6) of B cells
Tissue Wild-type CD19–/– TSK/+ CD19–/–TSK/+
Bone marrow % IgM– B220low 40.3 ± 3.0 34.9 ± 4.5 40.3 ± 2.4 35.7 ± 4.5
% IgM+ B220low 24.1 ± 4.4 25.1 ± 3.1 24.2 ± 4.7 21.7 ± 2.5
% IgM+ B220hi 15.2 ± 1.2 10.2 ± 2.1 13.3 ± 1.8 11.7 ± 1.6
Blood % IgM+ B220+ 40.7 ± 2.3 30.8 ± 1.1A 44.9 ± 2.0 26.7 ± 3.7B
# IgM+ B220+ 2.2 ± 0.4 2.1 ± 0.4 3.0 ± 0.5 1.8 ± 0.4
Spleen % IgM+ B220+ 56.8 ± 0.9 40.0 ± 3.3A 57.1 ± 2.2 37.4 ± 2.3A
# IgM+ B220+ 50.2 ± 3.4 31.4 ± 3.1B 54.4 ± 2.6 32.2 ± 3.1B
Peritoneal cavity % IgM+ B220+ 56.2 ± 2.6 27.6 ± 5.5A 67.1 ± 3.4A 26.7 ± 7.7A
# IgM+ B220+ 1.4 ± 0.2 0.5 ± 0.1B 1.1 ± 0.3 0.3 ± 0.1A
% CD5+ B220low 32.9 ± 2.1 10.1 ± 1.0A 17.0 ± 2.7A 6.8 ± 0.2A
# CD5+ B220low 0.9 ± 0.3 0.1 ± 0.1A 0.3 ± 0.1A 0.1 ± 0.1A
% CD5– B220hi 23.6 ± 0.9 24.8 ± 4.0 49.5 ± 4.0B 34.4 ± 16.3
# CD5– B220hi 0.7 ± 0.2 0.3 ± 0.1B 0.8 ± 0.2 0.5 ± 0.2
Values represent the number or percentage (± SD, n = 5) of lymphocytes (based on side and forward light scatter properties) expressing the indicated cell sur-
face markers. The background percentage of cells that were positive (<1%) was subtracted from the values shown. A,BThe number or percentage of cells was
significantly different from that of wild-type littermates: AP < 0.01, BP < 0.05.
The present study suggests that B cells play an impor-
tant role not only in autoantibody production, but also
in the development of cutaneous fibrosis itself. Indeed,
critical roles of B cells in disease expression have also
been suggested in animal models of other collagen dis-
eases. Elimination of B cells in lupus-prone mice results
in a complete abrogation of glomerulonephritis, vas-
culitis, and skin disease (33). Furthermore, lupus-prone
mice with B cells that cannot secrete Ab’s still develop
nephritis and vasculitis (33). This finding indicates that,
independent of autoantibody, B cells are essential for dis-
ease expression, either by serving as antigen-presenting
cells or by contributing directly to local inflammation
through cytokine secretion. Pathogenic autoantibodies
from B cells are also important, since K/BxN mice, a
model for human rheumatoid arthritis, have hyperactive
B cells that cause hyper-γ-globulinemia and produce
arthritogenic autoantibody (34). Collectively, B cells are
crucial for development of autoimmunity and disease
expression in systemic autoimmune models.
Although autoantibody production is a major char-
acteristic of TSK/+ mice, intrinsic B cell abnormalities
have not, to our knowledge, been previously identified.
We believe that the present study is the first to reveal
augmented B cell function in TSK/+ mice and the first
to demonstrate that autoimmunity in TSK/+ mice is
dependent on CD19 signaling. The increase in consti-
tutive CD19 and Vav tyrosine phosphorylation and Lyn
kinase activity in TSK/+ B cells (Figure 1) undoubtedly
increases the formation and activity of CD19/Lyn/Vav
complexes, which lowers base-line signaling thresholds
required for B cell activation (10, 19, 20). This is consis-
tent with enhanced BCR-mediated proliferation by
TSK/+ B cells (Figure 2b), since CD19 augments BCR
signaling (10, 16, 22). Downregulation of surface IgM
expression on B cells in TSK/+ mice (Figure 3) is similar
to what has been previously shown in other autoim-
mune strains of mice such as transgenic mice overex-
pressing CD19, CD22–/– mice, and SHP-1 defective
mev/mev mice (18, 21, 22). Taken together, these results
indicate that the B cell abnormalities observed in TSK/+
mice are due in part to augmented signaling through a
CD19-dependent pathway.
Although skin fibrosis and autoimmunity in TSK/+
mice were significantly inhibited in the absence of CD19
expression (Figures 5 and 6), the development of lung
emphysema and myocardial hypertrophy were not
affected (data not shown). These findings demonstrate
that TSK disease is likely to be multigenic, rather than
due to a single mutation in the Fbn-1 gene. In further
support of this, CD4 deficiency in TSK/+ mice results in
decreased cutaneous fibrosis but does not affect lung
emphysema or anti–topo I Ab levels (32). Some studies
also suggest that the abnormal microfibrils resulting
from the duplicated Fbn-1 gene are associated only with
the development of pulmonary emphysema, and not
with tissue hyperplasia and autoimmunity (7). Other
studies suggest that the mutated Fbn-1 gene contributes
to skin fibrosis and autoimmunity, but not to pul-
monary emphysema and cardiac hypertrophy (9). Thus,
the relationship of the duplicated Fbn-1 gene to autoim-
munity and hyperplasia of skin and internal organs
remains unclear, although additional genetic defects
that affect CD19 function in B cells are likely to exist in
linkage with the duplicated Fbn-1 gene in TSK mice.
In human SSc, B cells overexpress CD19 (15). In addi-
tion, various growth factors and cytokines that are part-
ly produced by immune cells have been suggested to
play central roles in the initiation and development of
fibrosis. Since TSK/+ B cells were chronically activated
in vivo (Figures 1 and 3), it can be hypothesized that
cytokines produced by activated B cells may contribute
to the induction of skin fibrosis in TSK/+ mice. Con-
sistent with this, TSK/+ B cells produced more IL-6
than did wild-type B cells in response to BCR and CD40
ligation (Figure 7a). Enhanced IL-6 production by
TSK/+ B cells was also eliminated by a loss in CD19
expression. IL-6 induces concentration-dependent
increases in the production of collagen and gly-
cosaminoglycans by dermal fibroblast (25). Serum IL-6
levels are higher in patients with SSc than in normal
controls, and IL-6 production by cultured PBMCs from
patients with SSc is augmented relative to normal con-
trols (23). Furthermore, function-blocking anti–IL-6
Ab’s significantly inhibit the production of procollagen
type I in cultured SSc fibroblasts (24). Moreover, Vav-
induced Rac1 activation leads to the production and
subsequent autocrine action of IL-6 (35). Therefore,
enhanced Vav tyrosine phosphorylation downstream of
CD19 in TSK/+ B cells (Figure 1b) may result in IL-6
overproduction that contributes in part to skin fibro-
sis in TSK/+ mice. Recent studies have demonstrated
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Figure 7
Hyperresponsiveness of B cells from TSK/+ mice.
(a) IL-6 production by B cells from mutant and
wild-type littermates. Spleen B cells were stimulat-
ed with either media alone or anti-IgM plus anti-
CD40 mAb’s for 48 hours. (b) IgG1 secretion by B
cells stimulated with IL-4. Spleen B cells were cul-
tured with either media alone or IL-4 plus LPS for
5 days. Cell supernatants were analyzed by ELISA
to determine the amount of secreted IL-6 or IgG1.
Each histogram shows the mean (± SD) results
obtained for six mice of each genotype. *P < 0.05.
the importance of IL-4 for the development of cuta-
neous fibrosis, since deficiency of IL-4Rα or IL-4 inhib-
ited skin fibrosis and autoantibody production (17, 26).
In the current study, TSK/+ B cells exhibited hyperre-
sponsiveness to IL-4 that was eliminated by CD19 
deficiency (Figure 7b). Therefore, it is also possible that
the hyperresponsiveness of TSK/+ B cells to IL-4 may
contribute to skin fibrosis and autoimmunity.
The presence of autoantibodies is a central feature of
human SSc, since specific autoantibodies are detected
in more than 90% of patients. In addition, anti–topo I
Ab levels closely correlate with disease activity and sever-
ity in human SSc. However, the pathogenic relationship
between systemic autoimmunity and the clinical mani-
festations of SSc including skin fibrosis remains
unknown, since autoantigens are generally intracellular
components critical for cell mitosis and autoantibodies
are not thought to contribute to tissue damage in SSc.
The current study indicates that autoantibody produc-
tion is linked to skin sclerosis through chronic B cell
activation that results from constitutively enhanced
CD19 signaling. Alternatively, the link between skin
fibrosis and autoimmunity may be the presence in
TSK/+ mice of anti–Fbn-1 autoantibodies that were
eliminated by CD19 deficiency (Figure 5), since normal
fibroblasts treated with anti–Fbn-1 autoantibodies dis-
play an activated phenotype overexpressing Fbn-1 as
well as some other ECM components (36). Taken
together, the present study suggests that B cells or cell
surface regulatory molecules on B cells, including
CD19, may be possible targets in the therapy of SSc.
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